Literature DB >> 20926078

Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction.

Fumiyuki Otsuka1, Kiyoshi Hibi, Ikuyoshi Kusama, Mitsuaki Endo, Masami Kosuge, Noriaki Iwahashi, Jun Okuda, Kengo Tsukahara, Toshiaki Ebina, Sunao Kojima, Seigo Sugiyama, Hisao Ogawa, Satoshi Umemura, Kazuo Kimura.   

Abstract

OBJECTIVE: Several studies in experimental animals have shown that statins stabilize atheromatous plaques by increasing fibrous-cap thickness. However, direct evidence linking the use of statins to the incidence of plaque rupture in humans is lacking. We investigated whether statin treatment before the onset of ST-elevation myocardial infarction (STEMI) influences the incidence of plaque rupture detected by intravascular ultrasound (IVUS).
METHODS: The study enrolled 458 patients with STEMI who were admitted within 6h from symptom onset. IVUS interrogation was performed before percutaneous coronary intervention.
RESULTS: Plaque ruptures were detected in 262 patients (57%). Patients with statin pretreatment (n=68) had a lower incidence of plaque rupture than those without (37% vs. 61%, p<0.001). Univariate analysis revealed that smoking (p=0.003), lower high-density lipoprotein cholesterol (p=0.001), and a lack of statin pretreatment (p<0.001) were associated with a higher incidence of plaque rupture. Multivariate logistic regression analysis identified statin pretreatment as a negative determinant of plaque rupture independent of age, gender, coronary risk factors, and all other medications (odds ratio 0.35; 95% CI 0.19-0.66, p=0.001). Positive remodeling was also associated with plaque rupture (p<0.001), and the relationship between statin pretreatment and a lower incidence of plaque rupture persisted after adjustment for positive remodeling (odds ratio 0.42; 95% CI 0.22-0.80, p=0.009).
CONCLUSIONS: Statin treatment before the onset of STEMI is associated with a lower incidence of plaque rupture, suggesting that the prevention of plaque rupture may be a crucial mechanism underlying clinical benefits associated with statins.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926078     DOI: 10.1016/j.atherosclerosis.2010.09.005

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease.

Authors:  Jeffrey J Siracuse; Kristina A Giles; Frank B Pomposelli; Allen D Hamdan; Mark C Wyers; Elliot L Chaikof; April E Nedeau; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2012-02-01       Impact factor: 4.268

2.  LDL Lowering After Acute Coronary Syndrome: Is Lower Better?

Authors:  Gautam Reddy; Vera Bittner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

3.  Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features.

Authors:  Firas Ghanem; Deepthi Vodnala; Jagadeesh K Kalavakunta; Sridevi Durga; Noah Thormeier; Prem Subramaniyam; Scott Abela; George S Abela
Journal:  J Biomed Res       Date:  2017-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.